FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Executive Summary
Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said
You may also be interested in...
PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011